Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	20.30B +34.9%
Revenue (ttm)	4.99B +11.5%
Net Income	407.48M +61.4%
EPS	0.77 +74.1%
Shares Out	530.60M
PE Ratio	49.08
Forward PE	28.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	377,501
Open	37.90
Previous Close	37.85
Day's Range	37.80 - 38.55
52-Week Range	24.18 - 38.55
Beta	1.13
Analysts	Buy
Price Target	36.55 (-4.44%)
Earnings Date	Oct 22, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,300
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2025, Vimian Group AB's revenue was 425.10 million, an increase of 13.42% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Financial numbers in EUR

Analyst Summary

According to 6 analysts, the average rating for VIMIAN stock is "Buy." The 12-month stock price target is kr 36.55, which is a decrease of -4.44% from the latest price.

Price Target

kr 36.55

(-4.44% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error